Actively Recruiting
Observational Study of Abrocitinib Treatment in Adults With Moderate to Severe Atopic Dermatitis and Its Real-Life Impact
Led by Pfizer · Updated on 2025-12-08
183
Participants Needed
30
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the safety and effects of Abrocitinib for adults with moderate to severe chronic atopic dermatitis, a long-lasting skin condition causing inflammation, redness, and irritation. The study focuses on real-life use of Abrocitinib to understand its impact and safety in this patient group. Participants must be over 18 years old without medical conditions that prevent using Abrocitinib. All participants will take Abrocitinib tablets once daily and may continue using medicated topical treatments alongside the study drug. The study lasts 24 months, during which participants will visit the clinic approximately five times, roughly once every 4 to 6 months. The study collects observational data to describe the effects and safety of Abrocitinib over this period. Participants will undergo assessments including skin evaluations using tools like the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI). Researchers will monitor symptoms such as itch severity and sleep quality, along with treatment adherence and any side effects. Safety and effectiveness will be reviewed regularly throughout the study and at its end, with ongoing observation of treatment patterns and patient-reported outcomes.
CONDITIONS
Brief Title
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years of age at inclusion
- Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis eligible for Abrocitinib
- Patients who have been informed of the study procedures and have signed consent
You will not qualify if you...
- Patients for whom Abrocitinib is contraindicated
- Patients unable to follow study procedures or respond to questions due to language, psychological, social, or geographical reasons
- Patients not affiliated with the French social security system
- Patients deprived of liberty, under guardianship, or unable to provide oral consent
- Patients participating in a clinical study assessing a medicinal treatment (registries and observatories allowed)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants receive Abrocitinib treatment and are observed for its effects on moderate to severe atopic dermatitis.
Multiple visits including baseline and follow-up visits up to 24 months
Duration - Up to 24 months
Participants are monitored over the long term to observe ongoing treatment effects and safety outcomes related to Abrocitinib use.
Follow-up visits at 12, 18, and 24 months
Trial Site Locations
Total: 30 locations
1
CHU Amiens-Picardie - Site Nord
Amiens, Somme, France, 80080
Actively Recruiting
2
CHU Besancon - Hopital Jean Minjoz
Besançon, France, 25000
Actively Recruiting
3
Polyclinique Reims Bezannes
Bezannes, France, 51430
Actively Recruiting
4
Chu Bordeaux Hopital Saint Andre
Bordeaux, France, 33075
Actively Recruiting
5
CHU Brest Hopital Morvan
Brest, France, 29609
Actively Recruiting
6
CHU de Caen
Caen, France, 14033
Actively Recruiting
7
Ch de Calais
Calais, France, 62107
Actively Recruiting
8
Ch William Morey
Chalon-sur-Saône, France, 71100
Actively Recruiting
9
CHU Clermont Ferrand - Hopital Gabriel Montpied
Clermont-Ferrand, France, 63000
Actively Recruiting
10
Chu Estaing
Clermont-Ferrand, France, 63003
Actively Recruiting
11
Hopital Henri Mondor
Créteil, France, 94010
Actively Recruiting
12
Chu Dijon
Dijon, France, 21000
Actively Recruiting
13
Hopital Franco Britannique
Levallois-Perret, France, 92300
Actively Recruiting
14
Hopital Claude Huriez
Lille, France, 59000
Actively Recruiting
15
CH de Martigues
Martigues, France, 13698
Actively Recruiting
16
CHU Montpellier
Montpellier, France, 34295
Actively Recruiting
17
Hopital Emile Muller
Mulhouse, France, 68070
Actively Recruiting
18
Hopital Hotel Dieu
Nantes, France, 44000
Actively Recruiting
19
Hopital Cochin
Paris, France, 75014
Actively Recruiting
20
Hopital Tenon
Paris, France, 75020
Actively Recruiting
21
Hopital Saint Louis (APHP) - Service Hematologic Senior
Paris, France, 75475
Actively Recruiting
22
CHU Lyon Sud
Pierre-Bénite, France, 69495
Actively Recruiting
23
Hopital Pontchaillou
Rennes, France, 35033
Actively Recruiting
24
Ch de Romans Sur Isere
Romans-sur-Isère, France, 26102
Actively Recruiting
25
Hopital Charles Nicolle
Rouen, France, 76031
Actively Recruiting
26
Chi Poissy Saint Germain En Laye
Saint-Germain-en-Laye, France, 78105
Actively Recruiting
27
Hopital Bégin
Saint-Mandé, France, 94160
Actively Recruiting
28
Hopital Larrey
Toulouse, France, 31000
Actively Recruiting
29
Ch de Valenciennes
Valenciennes, France, 59322
Actively Recruiting
30
CHU Nancy
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here